Javascript must be enabled to continue!
Effect of desmopressin on bleeding outcomes after native renal biopsy: a systematic review and meta-analysis
View through CrossRef
Abstract
Percutaneous kidney biopsy is a key diagnostic tool in nephrology but carries a risk of post-procedure bleeding, with complications ranging from minor hematomas to life-threatening hemorrhages. Desmopressin (DDAVP), a synthetic vasopressin analogue, has been used as a prophylactic agent to reduce the risk of bleeding. This systematic review and meta-analysis aims to resolve uncertainties by evaluating efficacy and safety outcomes in diverse cohorts, informing evidence-based practice for desmopressin use in native renal biopsy care. A comprehensive literature search was conducted across PubMed, Web of Science, Scopus, Cochrane Library, and ClinicalTrials.gov, covering all records up to May 2025 for randomized controlled trials that compared Desmopressin with placebo before native kidney biopsy. The primary outcome was bleeding events following kidney biopsy, with secondary outcomes focusing on adverse effects associated with Desmopressin use. A total of five randomized controlled trials (RCTs), including 717 patients undergoing native renal biopsy, were included in our study. The study found that desmopressin was significantly effective than placebo in reducing total bleeding events in 157 participants (RR 0.51, 95% CI [0.31, 0.83],
P
= 0.008). However, there was substantial heterogeneity, with no significant improvement in hematoma formation or blood transfusion needs. The safety parameters, including flushing incidence, systolic and diastolic blood pressure, and hemoglobin, were not significantly different between the desmopressin and placebo groups. The point estimates for the endpoints were generally consistent with no clinically significant difference between treatments. Evidence available suggests that while desmopressin reduces the cumulative incidence of bleeding after native renal biopsy, its negligible effect on clinically significant complications does not support its routine use in this setting. It did not affect clinically important endpoints such as hematoma formation or need for transfusion, and no difference in safety between the two groups was noted. It is concluded that there is no existing evidence to support the routine premedication with desmopressin before native renal biopsy, but in certain high-risk cases, its use may be contemplated until further research is pending. Further, adequately powered randomized trials are required to establish a definitive therapeutic benefit.
Springer Science and Business Media LLC
Title: Effect of desmopressin on bleeding outcomes after native renal biopsy: a systematic review and meta-analysis
Description:
Abstract
Percutaneous kidney biopsy is a key diagnostic tool in nephrology but carries a risk of post-procedure bleeding, with complications ranging from minor hematomas to life-threatening hemorrhages.
Desmopressin (DDAVP), a synthetic vasopressin analogue, has been used as a prophylactic agent to reduce the risk of bleeding.
This systematic review and meta-analysis aims to resolve uncertainties by evaluating efficacy and safety outcomes in diverse cohorts, informing evidence-based practice for desmopressin use in native renal biopsy care.
A comprehensive literature search was conducted across PubMed, Web of Science, Scopus, Cochrane Library, and ClinicalTrials.
gov, covering all records up to May 2025 for randomized controlled trials that compared Desmopressin with placebo before native kidney biopsy.
The primary outcome was bleeding events following kidney biopsy, with secondary outcomes focusing on adverse effects associated with Desmopressin use.
A total of five randomized controlled trials (RCTs), including 717 patients undergoing native renal biopsy, were included in our study.
The study found that desmopressin was significantly effective than placebo in reducing total bleeding events in 157 participants (RR 0.
51, 95% CI [0.
31, 0.
83],
P
= 0.
008).
However, there was substantial heterogeneity, with no significant improvement in hematoma formation or blood transfusion needs.
The safety parameters, including flushing incidence, systolic and diastolic blood pressure, and hemoglobin, were not significantly different between the desmopressin and placebo groups.
The point estimates for the endpoints were generally consistent with no clinically significant difference between treatments.
Evidence available suggests that while desmopressin reduces the cumulative incidence of bleeding after native renal biopsy, its negligible effect on clinically significant complications does not support its routine use in this setting.
It did not affect clinically important endpoints such as hematoma formation or need for transfusion, and no difference in safety between the two groups was noted.
It is concluded that there is no existing evidence to support the routine premedication with desmopressin before native renal biopsy, but in certain high-risk cases, its use may be contemplated until further research is pending.
Further, adequately powered randomized trials are required to establish a definitive therapeutic benefit.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
BackgroundA clinical dilemma exists in patients with CKD, ESKD, and after kidney transplantation, as they face concurrent risks of both thromboembolic and hemorrhagic complications...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Desmopressin stimulation testing: Response to intravenous and intranasal forms
Desmopressin stimulation testing: Response to intravenous and intranasal forms
IntroductionDesmopressin is commonly used to reduce bleeding in patients with mucocutaneous bleeding disorders and is available in both intravenous and intranasal forms. Given the ...
Comparing Desmopressin Plus Anticholinergics Versus Desmopressin Alone for Monosymptomatic Nocturnal Enuresis: A Systematic Review and Meta-Analysis
Comparing Desmopressin Plus Anticholinergics Versus Desmopressin Alone for Monosymptomatic Nocturnal Enuresis: A Systematic Review and Meta-Analysis
Context: Monosymptomatic nocturnal enuresis (MNE) is the most common type of enuresis. Desmopressin is the most widely used pharmacological treatment for MNE, while combination the...
Effects of desmopressin on thrombogenesis in aspirin‐induced platelet dysfunction
Effects of desmopressin on thrombogenesis in aspirin‐induced platelet dysfunction
Summary. Aspirin causes a coagulation disorder. Desmopressin has haemostatic effects by increasing the plasma levels of coagulation factor VIII and von Willebrand factor. The preci...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...

